MicroRNA-615-5p Regulates Angiogenesis and Tissue Repair by Targeting AKT/eNOS (Protein Kinase B/Endothelial Nitric Oxide Synthase) Signaling in Endothelial Cells.


Journal

Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803

Informations de publication

Date de publication:
07 2019
Historique:
pubmed: 17 5 2019
medline: 29 2 2020
entrez: 17 5 2019
Statut: ppublish

Résumé

Objective- In response to tissue injury, the appropriate progression of events in angiogenesis is controlled by a careful balance between pro and antiangiogenic factors. We aimed to identify and characterize microRNAs that regulate angiogenesis in response to tissue injury. Approach and Results- We show that in response to tissue injury, microRNA-615-5p (miR-615-5p) is rapidly induced and serves as an antiangiogenic microRNA by targeting endothelial cell VEGF (vascular endothelial growth factor)-AKT (protein kinase B)/eNOS (endothelial nitric oxide synthase) signaling in vitro and in vivo. MiR-615-5p expression is increased in wounds of diabetic db/db mice, in plasma of human subjects with acute coronary syndromes, and in plasma and skin of human subjects with diabetes mellitus. Ectopic expression of miR-615-5p markedly inhibited endothelial cell proliferation, migration, network tube formation in Matrigel, and the release of nitric oxide, whereas miR-615-5p neutralization had the opposite effects. Mechanistic studies using transcriptomic profiling, bioinformatics, 3' untranslated region reporter and microribonucleoprotein immunoprecipitation assays, and small interfering RNA dependency studies demonstrate that miR-615-5p inhibits the VEGF-AKT/eNOS signaling pathway in endothelial cells by targeting IGF2 (insulin-like growth factor 2) and RASSF2 (Ras-associating domain family member 2). Local delivery of miR-615-5p inhibitors, markedly increased angiogenesis, granulation tissue thickness, and wound closure rates in db/db mice, whereas miR-615-5p mimics impaired these effects. Systemic miR-615-5p neutralization improved skeletal muscle perfusion and angiogenesis after hindlimb ischemia in db/db mice. Finally, modulation of miR-615-5p expression dynamically regulated VEGF-induced AKT signaling and angiogenesis in human skin organoids as a model of tissue injury. Conclusions- These findings establish miR-615-5p as an inhibitor of VEGF-AKT/eNOS-mediated endothelial cell angiogenic responses and that manipulating miR-615-5p expression could provide a new target for angiogenic therapy in response to tissue injury. Visual Overview- An online visual overview is available for this article.

Identifiants

pubmed: 31092013
doi: 10.1161/ATVBAHA.119.312726
pmc: PMC6594892
mid: NIHMS1528631
doi:

Substances chimiques

MIRN615 microRNA, human 0
MicroRNAs 0
RASSF2 protein, human 0
Tumor Suppressor Proteins 0
Vascular Endothelial Growth Factor A 0
Nitric Oxide Synthase Type III EC 1.14.13.39
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1458-1474

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK034854
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL115141
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL148207
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL134849
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM115605
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL117994
Pays : United States

Références

Plast Reconstr Surg. 2011 Dec;128(6):673e-684e
pubmed: 22094769
Curr Opin Cardiol. 2007 Sep;22(5):458-63
pubmed: 17762548
Circulation. 2011 Jan 25;123(3):282-91
pubmed: 21220732
Nature. 2001 Dec 13;414(6865):813-20
pubmed: 11742414
J Surg Res. 2014 Jul;190(1):358-66
pubmed: 24814764
Genes Dev. 2016 Oct 15;30(20):2297-2309
pubmed: 27898394
Wound Repair Regen. 2010 Jul-Aug;18(4):426-32
pubmed: 20546556
Circulation. 2002 Mar 26;105(12):1497-502
pubmed: 11914261
Diabet Med. 2006 Jun;23(6):594-608
pubmed: 16759300
Am J Transl Res. 2016 Sep 15;8(9):3666-3677
pubmed: 27725849
Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1372-82
pubmed: 22499991
Adv Biomed Res. 2016 Jul 29;5:129
pubmed: 27563639
Curr Drug Targets. 2010 Aug;11(8):943-9
pubmed: 20415654
Biochim Biophys Acta. 2007 Nov;1773(11):1645-52
pubmed: 17609119
Trans Am Clin Climatol Assoc. 2016;127:224-234
pubmed: 28066055
Cancer Res. 2005 Aug 15;65(16):7065-70
pubmed: 16103053
Diabetes Care. 2011 May;34 Suppl 2:S285-90
pubmed: 21525470
EMBO Mol Med. 2014 Jul 25;6(9):1105-20
pubmed: 25063693
Circ Res. 2013 Nov 8;113(11):1231-41
pubmed: 24047927
Cell. 2011 Sep 16;146(6):873-87
pubmed: 21925313
Nature. 1999 Jun 10;399(6736):601-5
pubmed: 10376603
Stem Cell Res. 2017 Apr;20:94-104
pubmed: 28340487
Oncogene. 2015 Mar 26;34(13):1629-40
pubmed: 24769899
Lancet. 2011 Jun 4;377(9781):1929-37
pubmed: 21621834
Diabetes Care. 2007 Jun;30(6):1351-6
pubmed: 17337492
J Clin Invest. 2013 Aug;123(8):3190-200
pubmed: 23908119
Circ Res. 2007 Oct 26;101(9):948-56
pubmed: 17823371
Lancet. 2005 Nov 12;366(9498):1736-43
pubmed: 16291068
Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12865-70
pubmed: 25136137
Int J Clin Exp Pathol. 2014 Oct 15;7(11):8112-7
pubmed: 25550859
Mol Vis. 2015 Mar 07;21:224-35
pubmed: 25802486
Cancer Cell. 2010 Aug 9;18(2):171-84
pubmed: 20708158
Circ Res. 2015 Apr 24;116(9):1561-78
pubmed: 25908729
J Clin Invest. 2005 Aug;115(8):2119-27
pubmed: 16075056
Endocr Rev. 2017 Apr 1;38(2):145-168
pubmed: 28323921
Gastroenterology. 2005 Jul;129(1):156-69
pubmed: 16012945
Cardiovasc Res. 2012 Jul 1;95(1):7-18
pubmed: 22492672
Circ Res. 2016 Jun 24;119(1):91-112
pubmed: 27340270
Cell. 2005 Mar 11;120(5):635-47
pubmed: 15766527
J Mol Endocrinol. 2010 Oct;45(4):219-28
pubmed: 20639404
Am J Physiol Renal Physiol. 2005 May;288(5):F871-80
pubmed: 15821252
JACC Basic Transl Sci. 2017 Oct;2(5):503-512
pubmed: 29430558
Blood. 2011 Dec 8;118(24):6461-4
pubmed: 21828132
FASEB J. 2019 Apr;33(4):5599-5614
pubmed: 30668922
Clin Cardiol. 2004 May;27(5):281-6
pubmed: 15188944
J Mol Cell Cardiol. 2003 Feb;35(2):185-93
pubmed: 12606259
Cardiovasc Res. 2016 May 1;110(1):6-22
pubmed: 26912672
Ann Surg. 2011 Feb;253(2):402-9
pubmed: 21217515
Nat Rev Cancer. 2008 Aug;8(8):592-603
pubmed: 18650835
JCI Insight. 2017 Mar 9;2(5):e90651
pubmed: 28289712
Int J Mol Sci. 2015 May 18;16(5):11294-322
pubmed: 25993296
Blood. 2011 Dec 8;118(24):6450-60
pubmed: 21828131
Cardiovasc Res. 2017 Jul 1;113(9):1024-1034
pubmed: 28505257
J Am Coll Cardiol. 2008 Jul 29;52(5):387-93
pubmed: 18652948
Circulation. 2008 Jul 1;118(1):58-65
pubmed: 18559703
Ann Plast Surg. 2006 Apr;56(4):418-22
pubmed: 16557076
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):870-879
pubmed: 29449333
J Mol Cell Cardiol. 2016 Feb;91:151-9
pubmed: 26776318
Int J Mol Sci. 2017 Jul 03;18(7):
pubmed: 28671607
Circulation. 2003 Oct 21;108(16):1933-8
pubmed: 14504183
Dev Cell. 2008 Aug;15(2):261-71
pubmed: 18694565
Lancet. 2002 Jul 6;360(9326):23-33
pubmed: 12114037
Curr Vasc Pharmacol. 2012 Jan;10(1):77-93
pubmed: 22112349
Physiol Rev. 2011 Jul;91(3):827-87
pubmed: 21742789
Lancet. 1999 Aug 7;354(9177):447-55
pubmed: 10465168
J Cell Commun Signal. 2016 Dec;10(4):347-354
pubmed: 27619687
N Engl J Med. 1995 Dec 28;333(26):1757-63
pubmed: 7491141
Trends Cardiovasc Med. 2019 Apr;29(3):131-137
pubmed: 30143275
Vasc Med. 2012 Jun;17(3):174-92
pubmed: 22496126
J Clin Invest. 2012 Jun;122(6):1973-90
pubmed: 22622040
Hum Gene Ther. 2006 Jun;17(6):683-91
pubmed: 16776576
Methods Enzymol. 2008;445:303-29
pubmed: 19022065
Lancet. 2000 Jan 22;355(9200):253-9
pubmed: 10675071
Circ Res. 2014 Jan 3;114(1):32-40
pubmed: 24084690
Circulation. 1998 Mar 31;97(12):1108-10
pubmed: 9537334
Am Heart J. 2007 May;153(5):874-80
pubmed: 17452167
J Am Coll Cardiol. 2000 Mar 15;35(4):968-73
pubmed: 10732896
PLoS One. 2013 May 28;8(5):e64434
pubmed: 23724047
Ageing Res Rev. 2009 Oct;8(4):306-13
pubmed: 19389489
J Biol Chem. 2014 Jan 3;289(1):510-9
pubmed: 24235146
Br J Anaesth. 2010 May;104(5):606-12
pubmed: 20348139
Cold Spring Harb Perspect Med. 2013 Feb 01;3(2):a006643
pubmed: 23169571
Curr Vasc Pharmacol. 2013 May 13;:
pubmed: 23713860
Circulation. 2011 Oct 18;124(16):1765-73
pubmed: 21947297
Int J Cancer. 2007 Jan 1;120(1):32-8
pubmed: 17013896
FASEB J. 2016 Sep;30(9):3216-26
pubmed: 27297585
J Biol Chem. 2003 Jul 25;278(30):28045-51
pubmed: 12732644
Cell Physiol Biochem. 2017;42(2):506-518
pubmed: 28578351

Auteurs

Basak Icli (B)

From the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Winona Wu (W)

From the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Denizhan Ozdemir (D)

From the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Department of Medical Biology, Hacettepe University, Ankara, Turkey (D.O.).

Hao Li (H)

From the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Henry S Cheng (HS)

From the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Stefan Haemmig (S)

From the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Xin Liu (X)

From the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Giorgio Giatsidis (G)

Division of Plastic Surgery, Department of Surgery (G.G., D.P.O.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Seyma Nazli Avci (SN)

From the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Nathan Lee (N)

From the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Raphael Boesch Guimaraes (RB)

Instituto de Cardiologia do Rio Grande do Sul, Fundação Universitária de Cardiologia (ICFUC), Porto Alegre, RS, Brazil (B.G., A.M.).

Andre Manica (A)

Instituto de Cardiologia do Rio Grande do Sul, Fundação Universitária de Cardiologia (ICFUC), Porto Alegre, RS, Brazil (B.G., A.M.).

Julio F Marchini (JF)

Heart Institute, University of São Paulo Medical School, Brazil (J.F.M.).

Stein Erik Rynning (SE)

Department of Cardiac Surgery, LHL Hospital Gardermoen, Jessheim, Norway (S.E.R., I.R.).

Ivar Risnes (I)

Department of Cardiac Surgery, LHL Hospital Gardermoen, Jessheim, Norway (S.E.R., I.R.).

Ivana Hollan (I)

From the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Department of Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Norway (I.H.).

Kevin Croce (K)

From the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Xianbin Yang (X)

AM Biotechnologies, LLC, Houston, TX (X.Y.).

Dennis P Orgill (DP)

Division of Plastic Surgery, Department of Surgery (G.G., D.P.O.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Mark W Feinberg (MW)

From the Cardiovascular Division, Department of Medicine (B.L., W.W., D.O., H.L., H.S.C., S.H., X.L., S.N.A., N.L., I.H., K.C., M.W.F.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH